| 1 | Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. (Lo AC, Liu A, Liu Q, Yasui Y, Castellino SM, Kelly KM, Hererra AF, Friedberg JW, Friedman DL, Schwartz CL, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine LS, Hodgson DC) JAMA Netw Open 2024 Jan 02;7(1):e2351062 13 Citations |
| 1 | Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. (Chow EJ, Aggarwal S, Doody DR, Aplenc R, Armenian SH, Baker KS, Bhatia S, Blythe N, Colan SD, Constine LS, Freyer DR, Kopp LM, Laverdière C, Leisenring WM, Sasaki N, Vrooman LM, Asselin BL, Schwartz CL, Lipshultz SE) J Clin Oncol 2023 Apr 20;41(12):2248-2257 51 Citations |
| 1 | Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. (Chow EJ, Aplenc R, Vrooman LM, Doody DR, Huang YV, Aggarwal S, Armenian SH, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Leisenring WM, Asselin BL, Schwartz CL, Lipshultz SE) Cancer 2022 Feb 15;128(4):788-796 45 Citations |
| 6 | Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes. (Schloemer NJ, Brickler M, Hoffmann R, Pan A, Simpson P, McFadden V, Block J, Tower RL 2nd, Burke MJ) J Pediatr Hematol Oncol 2017 Jul;39(5):e254-e258 18 Citations |
| 1 | Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. (Schwartz CL, Wexler LH, Krailo MD, Teot LA, Devidas M, Steinherz LJ, Goorin AM, Gebhardt MC, Healey JH, Sato JK, Meyers PA, Grier HE, Bernstein ML, Lipshultz SE) Pediatr Blood Cancer 2016 Jan;63(1):54-61 84 Citations |
| 1 | Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. (Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Constine LS, Freyer DR, Lipshultz SE, Armenian SH) J Clin Oncol 2015 Aug 20;33(24):2639-45 86 Citations |
| 3 | Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model. (Dickey JS, Gonzalez Y, Aryal B, Mog S, Nakamura AJ, Redon CE, Baxa U, Rosen E, Cheng G, Zielonka J, Parekh P, Mason KP, Joseph J, Kalyanaraman B, Bonner W, Herman E, Shacter E, Rao VA) PLoS One 2013;8(8):e70575 62 Citations |
